SWTX May 2024 25.000 put
OPR - OPR Delayed Price. Currency in USD
Add to watchlist
As of 03:55PM EDT. Market open.
| Previous Close | 0.4000 |
| Open | N/A |
| Bid | 0.0000 |
| Ask | 5.0000 |
| Strike | 25.00 |
| Expire Date | 2024-05-17 |
| Day's Range | 0.4000 - 0.4000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 1 |
Simply Wall St.Here's Why We're Not Too Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- GuruFocus.com
SpringWorks Therapeutics Inc (SWTX) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...
Insights into SWTX's robust Q1 performance, strategic initiatives, and forward-looking financial health.
GlobeNewswireSpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates
– Achieved $21.0 million in OGSIVEO® (nirogacestat) net product revenue in the first quarter – – Received validation from the EMA for MAA of nirogacestat for the treatment of adults with desmoid tumors – – Initiated rolling submission of NDA to the FDA for mirdametinib for the treatment of children and adults with NF1-PN – – Phase 2b ReNeu trial results accepted for oral presentation at the 2024 ASCO Annual Meeting – STAMFORD, Conn., May 02, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc
© 2024 Yahoo. All rights reserved.